Contribute Try STAT+ Today

LOS ANGELES — This city is now home to its very first biotech venture firm: Dr. Beth Seidenberg, a general partner at Kleiner Perkins, will now be heading up a $320 million fund called Westlake Village BioPartners dedicated exclusively to the life sciences — and, potentially, helping build up the LA area as a new biotech hub.

Seidenberg, former chief medical officer of Amgen, is bringing on board Sean Harper — who by January will end his tenure as R&D head at the Los Angeles-area biotech. Some of the better-known companies in Seidenberg’s portfolio include ovarian cancer therapeutics company Tesaro, allogeneic T cell company Atara Biotherapeutics, and epigenetics player Epizyme.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.